Profile Core value Main business Legitimacy Social Responsibility
    Patents Research Direction Technology Strength
  API Intermediate l Side chain for pacltaxel & docetaxel
  Production management QC Quality System branch factory
 
logn  

username:

 password:

 

  home
 
  Products Center
  API
Paclitaxel (Natural) USP30
Paclitaxel Semi-Synthetic USP30
Docetaxel Anhydrous
Docetaxel Trihydrate
Irinotecan Hcl Trihydrate
Palonosetron Hydrochloride
Etoposide
Fludarabine phosphate
  Intermediate
10-DAB III(10-Deacetyl Baccatin III) 99%
Baccatin III 98%
9-DHB
Sequoyitol
Podophyllotoxin
4’-Demethyl-epi- Podophyllotoxin
5-Fluoroorotic Acid Hydrate
  Side chain for pacltaxel & docetaxel
(2R,3S)-3-Phenylisoserine Hydrochloride
(2R,3S)-N-benzoyl-3-Phenylisoserine Methyl Ester
(2R,3S)-N-tert-butoxycarbonyl-3-Phenyl isoserine methyl ester
(3R,4S)-3-hydroxy-4-phenyl-2-azetidinone
   
 
Your location:Home>>R&D>>Research Direction
 
 

     Jinhe is devoted to R&D on extraction, synthesization,seperation, and purification of anticancer drum raw materials and the intermediates. Currently Jinhe is mainly directed at:

     ●The extraction optimization and purification process of botanical APIs and intermediates.

     ●The synthesization route of botanical Anti-cancer drug, such as Paclitaxel, docetaxel, Irinotecan and Etoposide etc.

     ●The synthesization route of Paclitaxel and its
         optimization research;

     ●The synthesis process of other anticancer APIs.

 

 

 
 
 
CopyRight(C)2006,Shanghai Jinhe Bio-Technology Co.,Ltd. All Rights Reserved. Supported by ChemNet ChinaChemNet Toocle ChemNet
HOME About us Products R & D Production and QA Contact us CHINESE